WO2004050126A3 - Compositions for treating or preventing angiogenesis-dependent symptoms - Google Patents

Compositions for treating or preventing angiogenesis-dependent symptoms Download PDF

Info

Publication number
WO2004050126A3
WO2004050126A3 PCT/JP2003/015400 JP0315400W WO2004050126A3 WO 2004050126 A3 WO2004050126 A3 WO 2004050126A3 JP 0315400 W JP0315400 W JP 0315400W WO 2004050126 A3 WO2004050126 A3 WO 2004050126A3
Authority
WO
WIPO (PCT)
Prior art keywords
treating
dependent symptoms
angiogenesis
compositions
plasmid dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2003/015400
Other languages
French (fr)
Other versions
WO2004050126A2 (en
Inventor
Kazuya Hiraoka
Seiji Yamamoto
Yasufumi Kaneda
Ryuichi Morishita
Toshio Ogihara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anges Inc
Original Assignee
Anges MG Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anges MG Inc filed Critical Anges MG Inc
Priority to AU2003302590A priority Critical patent/AU2003302590B2/en
Priority to DE60333476T priority patent/DE60333476D1/en
Priority to AT03812366T priority patent/ATE474604T1/en
Priority to CA002507534A priority patent/CA2507534A1/en
Priority to US10/536,274 priority patent/US7259149B2/en
Priority to EP03812366A priority patent/EP1567197B1/en
Priority to JP2004556884A priority patent/JP4623719B2/en
Publication of WO2004050126A2 publication Critical patent/WO2004050126A2/en
Publication of WO2004050126A3 publication Critical patent/WO2004050126A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0016—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

A method for enhancing the transfection efficiency of naked plasmid DNA in treating and/or preventing angiogenesis-dependent symptoms is provided by the present inventions. According to the present method, a suitable naked plasmid DNA is subjected for intramuscular injection under increased pressure inside the muscle or hyperbaric oxygen. Angiogenesis-dependent symptoms, including wounds, inflammatory diseases, critical limb ischemia, ischemic heart diseases, cerebral infarction, diabetic neuropathy, spinal canal stenosis, etc., may be treated by the present methods.
PCT/JP2003/015400 2002-12-02 2003-12-02 Compositions for treating or preventing angiogenesis-dependent symptoms Ceased WO2004050126A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2003302590A AU2003302590B2 (en) 2002-12-02 2003-12-02 Compositions for treating or preventing angiogenesis-dependent symptoms
DE60333476T DE60333476D1 (en) 2002-12-02 2003-12-02 COMPOSITIONS FOR TREATING OR PREVENTING ANGIOGENESIS-DEPENDENT SYMPTOMS
AT03812366T ATE474604T1 (en) 2002-12-02 2003-12-02 COMPOSITIONS FOR THE TREATMENT OR PREVENTION OF ANGIOGENESIS-DEPENDENT SYMPTOMS
CA002507534A CA2507534A1 (en) 2002-12-02 2003-12-02 Methods for treating or preventing angiogenesis-dependent symptoms
US10/536,274 US7259149B2 (en) 2002-12-02 2003-12-02 Methods for treating or preventing angiogenesis-dependent symptoms
EP03812366A EP1567197B1 (en) 2002-12-02 2003-12-02 Compositions for treating or preventing angiogenesis-dependent symptoms
JP2004556884A JP4623719B2 (en) 2002-12-02 2003-12-02 Methods for treating or preventing angiogenesis-dependent symptoms

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43047802P 2002-12-02 2002-12-02
US60/430,478 2002-12-02

Publications (2)

Publication Number Publication Date
WO2004050126A2 WO2004050126A2 (en) 2004-06-17
WO2004050126A3 true WO2004050126A3 (en) 2004-09-30

Family

ID=32469479

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2003/015400 Ceased WO2004050126A2 (en) 2002-12-02 2003-12-02 Compositions for treating or preventing angiogenesis-dependent symptoms

Country Status (9)

Country Link
US (1) US7259149B2 (en)
EP (1) EP1567197B1 (en)
JP (1) JP4623719B2 (en)
CN (1) CN1717254A (en)
AT (1) ATE474604T1 (en)
AU (1) AU2003302590B2 (en)
CA (1) CA2507534A1 (en)
DE (1) DE60333476D1 (en)
WO (1) WO2004050126A2 (en)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU778826B2 (en) * 1999-10-29 2004-12-23 Anges Mg, Inc. Gene therapy for diabetic ischemic disease
EP1810696A4 (en) * 2004-10-29 2008-03-05 Anges Mg Inc Gene therapy for treatment of cardiac failure
US20090214496A1 (en) * 2006-01-30 2009-08-27 Licentia Ltd. Bmx/etk tyrosine kinase gene therapy materials and methods
RU2542385C2 (en) * 2012-08-31 2015-02-20 Общество с ограниченной ответственностью "НекстГен" Method for preparing pharmaceutical composition for inducing angiogenesis in tissues, pharmaceutical composition prepared by this method, and method of treating individual's tissue and/or organ ischemia
US20180066223A1 (en) 2015-04-17 2018-03-08 Xcell Biosciences, Inc. Cancer cell enrichment system
RU2612497C2 (en) 2015-05-26 2017-03-09 Общество с ограниченной ответственностью "НекстГен" Optimized nucleotide sequence and pharmaceutical compositions based thereon with sustained vegf transgene expression

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137707A1 (en) * 1997-12-30 2002-09-26 Monahan Sean D. Intravascular delivery of non-viral nucleic acid

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5941431U (en) * 1982-09-07 1984-03-16 斎藤　春雄 Emergency escape door device for high pressure treatment tank
JPS6183121A (en) * 1984-10-01 1986-04-26 Green Cross Corp:The Remedy for ischemic ulcer
AU736301B2 (en) 1996-05-01 2001-07-26 Imarx Therapeutics, Inc. Methods for delivering compounds into a cell
US6312663B1 (en) * 1999-03-19 2001-11-06 Joseph V. Boykin, Jr. Prediction of diabetes impaired wound healing by urinary nitrate assay
JP2002541829A (en) * 1999-04-16 2002-12-10 イエール・ユニバーシテイ ENOS variants useful for gene therapy and therapeutic screening
JP2001017188A (en) * 1999-04-22 2001-01-23 Kyowa Hakko Kogyo Co Ltd Novel VEGF / PDGF-like factor
WO2002000258A1 (en) * 2000-06-27 2002-01-03 Anges Mg, Inc. Medicinal compositions for angiogenic therapy
EP1541312B1 (en) * 2002-07-18 2012-05-30 Mitsubishi Rayon Co., Ltd. Prepreg and method for production
JP4420633B2 (en) * 2002-08-08 2010-02-24 アンジェスＭｇ株式会社 Anti-angiogenic agent
ES2302980T5 (en) * 2002-11-28 2015-12-01 Mitsubishi Rayon Co., Ltd. Procedures for the production of fiber reinforced composite material

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137707A1 (en) * 1997-12-30 2002-09-26 Monahan Sean D. Intravascular delivery of non-viral nucleic acid

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CIRCULATION, vol. 108, no. 21, 25 November 2003 (2003-11-25), pages 2689 - 2696, ISSN: 0009-7322 (ISSN print) *
CIRCULATION, vol. 97, no. 12, 31 March 1998 (1998-03-31), pages 1114 - 1123, ISSN: 0009-7322 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 25 November 2003 (2003-11-25), HIRAOKA KAZUYA ET AL: "Enhanced therapeutic angiogenesis by cotransfection of prostacyclin synthase gene or optimization of intramuscular injection of naked plasmid DNA.", XP002277369, Database accession no. PREV200400009718 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 31 March 1998 (1998-03-31), BAUMGARTNER IRIS ET AL: "Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia", XP002277366, Database accession no. PREV199800207109 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; February 2001 (2001-02-01), TANIYAMA Y ET AL: "Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rat and rabbit hindlimb ischemia models: Preclinical study for treatment of peripheral arterial disease", XP002277367, Database accession no. PREV200100114748 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; March 2002 (2002-03-01), TANIYAMA Y ET AL: "Development of safe and efficient novel nonviral gene transfer using ultrasound: Enhancement of transfection efficiency of naked plasmid DNA in skeletal muscle", XP002277365, Database accession no. PREV200200261758 *
DATABASE BIOSIS [online] BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; May 2002 (2002-05-01), COMEROTA ANTHONY J ET AL: "Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: Preliminary results of a phase I trial", XP002277368, Database accession no. PREV200200358126 *
GENE THERAPY, vol. 8, no. 3, February 2001 (2001-02-01), pages 181 - 189, ISSN: 0969-7128 *
GENE THERAPY, vol. 9, no. 6, March 2002 (2002-03-01), pages 372 - 380, ISSN: 0969-7128 *
JOURNAL OF VASCULAR SURGERY, vol. 35, no. 5, May 2002 (2002-05-01), pages 930 - 936, ISSN: 0741-5214 *

Also Published As

Publication number Publication date
DE60333476D1 (en) 2010-09-02
EP1567197B1 (en) 2010-07-21
WO2004050126A2 (en) 2004-06-17
ATE474604T1 (en) 2010-08-15
EP1567197A2 (en) 2005-08-31
AU2003302590B2 (en) 2008-11-06
US20060135452A1 (en) 2006-06-22
JP4623719B2 (en) 2011-02-02
CN1717254A (en) 2006-01-04
JP2006511515A (en) 2006-04-06
US7259149B2 (en) 2007-08-21
CA2507534A1 (en) 2004-06-17
AU2003302590A1 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
WO2009050506A3 (en) Combination 059
WO2006040688A3 (en) Inhibitors of acetylcholinesterase for treating skin diseases
SG146682A1 (en) Modulation of eif4e expression
WO2003025149A3 (en) Cell populations which co-express cd49c and cd90
WO2010045509A3 (en) Modulation of factor 11 expression
TW200637488A (en) Compositions containing botanical extracts rich in phlorizin and methods for using such compositions in blood glucose modification and to affect aging
WO2007024441A3 (en) Compositions of cells enriched for combinations of various stem and progenitor cell populations, methods of use thereof and methods of private banking thereof
WO2005065269A3 (en) Compositions and method for decreasing the appearance of skin wrinkles
WO2007101232A3 (en) Inhibition of jak2 as a treatment of pulmonary arterial hypertension
WO2005099716A3 (en) Method for analyzing the biological age of a subject
WO2009152480A3 (en) Methods to treat solid tumors
NO20061625L (en) Treatment and / or prevention of urinary incontinence using prodrugs of gaba analogues
WO2005107771A3 (en) Composition comprising a survivin oligonucleotide and gemcitabine for the treatment of cancer
PL371205A1 (en) Composition inhibiting matrix-metallproteinases for the treatment of neoplastic diseases
WO2004004653A3 (en) Methods for treating psychosis associated with interferon-alpha therapy
WO2003039453A3 (en) Novel benzoyl peroxide compositions for the treatment of dermatological disorders and methods for their use
WO2004002239A3 (en) Purified amylase inhibitor and novel process for obtaining the same
DE60333476D1 (en) COMPOSITIONS FOR TREATING OR PREVENTING ANGIOGENESIS-DEPENDENT SYMPTOMS
PL1715890T3 (en) Ctgf as target for the therapy of microalbuminuria in patients with diabetic nephropathy
WO2006021002A3 (en) Compounds useful for inhibiting chk1
WO2006023452A3 (en) Cyclosporin analogs for the treatment of immunoregulatory disorders and respiratory diseases
WO2004043373A3 (en) Precursor n-acetylgalactosamine-4-sulfatase, methods of treatment using said enzyme and methods for producing and purifying said enzyme
WO2003022203A3 (en) Products and methods for treating microbial infections
IL164314A (en) Method to inhibit cell growth using oligonucleotides
WO2009029836A3 (en) Nitrite and nitrite-metheme therapy to detoxify stroma-free hemoglobin based blood substitutes

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2003302590

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2507534

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004556884

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 20038A45974

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2003812366

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003812366

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006135452

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10536274

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10536274

Country of ref document: US